Hormone-Dependent Cancers (GRC) Gordon Research Conference - Mechanisms to Tailored Therapeutics

The Gordon Research Conference (GRC) on Hormone-Dependent Cancers: Mechanisms to Tailored Therapeutics (August 16-21, 2015 Sunday River Resort, Newry, ME), will bring together an outstanding faculty of new and more established scientists and translational researchers to explore molecular mechanisms of disease and strategize about new targeted therapies for hormone-dependent cancers. Hormones influence not only breast and prostate cancer, the two most common hormone-dependent cancers, but also have a major impact on less common hormone-sensitive malignancies (e.g. ovary, testes, endometrium) as well as human cancers recently discovered to be hormone sensitive (e.g. lung, liver). Developing a means to more specifically treat and ideally prevent hormone-dependent cancers is of critical importance given the significant impact these malignancies have on human health and the economic burden of disease. An in depth understanding of hormone action in regulating diverse cellular processes, cancer phenotypes and drug responsiveness is essential for the development of effective and well tolerated treatment strategies. The 2015 GRC is designed to maximize interaction between participants, in order to engender creativity and cross-fertilization of ideas across multiple disciplines while fostering mentorship of early career scientists. Scientists and clinicians from both academia and industry with expertise in contemporary ‘omics’, transcriptional control, cell signaling, human disease modeling and clinical translation will provide a stimulating and engaging format for interaction and fruitful exchange of scientific ideas common to overlapping research fields, such that novel concepts emerge, scientific collaborations are formed, and new translational opportunities are revealed.
+ show speakers and program
Keynote Session: Novel Approaches for Cancer Treatment
Jason Carroll, Wayne Tilley / William Hahn / Peter Jones

Functional Genomics and Epigenomics: Informing Biology and Defining Novel Targets
Lisa Butler, Steffi Oesterreich / X. Shirley Liu / Sohrab Shah / Scott Tomlins

Signaling Cross Talk: Driving Disease Progression and Treatment Resistance
Charlotte Bevan, Frank Claessens / Patricia Elizalde / Lori Friedman

Hormone Receptor Structure and Mutations in Endocrine Resistance
Geoffrey Greene, Jennifer Richer / Sarat Chandarlapaty / Scott Dehm / Matthew Ellis

Metastasis: Models and Mechanisms
Daniel Frigo, Christopher Ormandy / Ingunn Holen / Alana Welm

Patient Derived Models of Cancer Initiation and Treatment Resistance
Theresa Hickey, Ganesh Raj / Alex Swarbrick / Renea Taylor / Valerie Weaver

Tumor Heterogeneity and Evolution
Scott Cramer, Gail Prins / Senthil Muthuswamy / Kornelia Polyack

Novel Targets and Agents: Advancement to the Clinic
Felix Feng, Carol Lange / Suzanne Conzen / Naomi Laing / Donald McDonnell

Keynote Session: Future of Cancer Research – Challenges and Solutions
Robert Clarke, Gail Risbridger / Myles Brown / Carlo Palmieri / Chris Sweeney

16 Aug - 21 Aug 2015